Fuji Pharma Co., Ltd.

4554.T
Drug Manufacturers - Specialty & Generic
2026/11/20 13:29 Updated
Market Cap: $285.8M (¥45.4B)
Stock Price: $10.94 (¥1,737)
Exchange Rate: 1 USD = ¥158.73

Fuji Pharma Co., Ltd. Supplemental Materials for the Fiscal Year Ended September 2026

Published an overview of consolidated results for the fiscal year ended September 2026. Revenue was 59,250 hundred million yen (revised), gross profit margin declined to 39.0%, operating income increased year-over-year, and an impairment loss on available-for-sale securities of 2,000 hundred million yen was recorded as an extraordinary loss. By segment, women's healthcare, biosimilars, and CMO continued to drive growth. The full-year forecast shows the revised projection and differences compared with the prior year.

Importance:
Page Updated: November 10, 2026
IR Disclosure Date: November 10, 2026

Key Figures

  • Revenue: 59,250 hundred million yen (revised forecast) Specified cumulative results
  • Operating Income: 6,355 hundred million yen
  • Net Income Attributable to Owners of Parent: 2,831 hundred million yen

AI要約

Overview of Results

Consolidated results for the fiscal year ended September 2026 achieved revenue of 59,250 hundred million yen (compared with the revised forecast), gross profit of 24,321 hundred million yen, and operating income of 6,355 hundred million yen, all increasing year-over-year. Meanwhile, ordinary income was 6,176 hundred million yen and net income was 2,831 hundred million yen, showing slight declines. This was affected by an impairment loss on available-for-sale securities of 2,000 hundred million yen recorded as an extraordinary loss. EBITDA reached 10,562 hundred million yen, and gross profit margin declined to 39.0% against a backdrop of increased expenses including foreign exchange impacts. By segment, women's healthcare, biosimilars, and CMO continued to drive growth.

Medium- to Long-term Outlook and Strategy

All three growth strategies in the medium-term management plan (women's healthcare, biosimilars, and global CMO) are maintaining growth. In the segment revenue breakdown, expansion in women's healthcare and biosimilars continues. The launch status of new drugs and generics and the inclusion of drugs in reimbursement pricing are expected to affect future performance. The full-year forecast reflects the revised level, and attention should be paid to the impacts of foreign exchange and rising raw material costs.

Revenue Trend

Operating Income Trend

Gross Margin Trend

Segment Revenue

Forecast vs Actual Comparison

This page uses AI to summarize IR materials from TDnet. Please refer to the original document for investment decisions.

Fuji Pharma Co., Ltd.

Company overview · Stock price · Financial data · All IR

View company page →